DVYSR Relative Valuation - Devyser Diagnostics AB - Alpha Spread
D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 118.5 SEK 1.28% Market Closed
Market Cap: 2B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Relative Value

The Relative Value of one DVYSR stock under the Base Case scenario is 179.19 SEK. Compared to the current market price of 118.5 SEK, Devyser Diagnostics AB is Undervalued by 34%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DVYSR Relative Value
Base Case
179.19 SEK
Undervaluation 34%
Relative Value
Price
D
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
19
vs Industry
47
Median 3Y
9.1
Median 5Y
9.1
Industry
7.7
Forward
8.2
vs History
vs Industry
Median 3Y
-27.7
Median 5Y
-27.7
Industry
23.9
Forward
-37.5
vs History
vs Industry
Median 3Y
-29.2
Median 5Y
-29.2
Industry
22.2
vs History
vs Industry
Median 3Y
-15.4
Median 5Y
-15.4
Industry
24
vs History
0
vs Industry
19
Median 3Y
3
Median 5Y
3
Industry
2.5
vs History
5
vs Industry
41
Median 3Y
6.6
Median 5Y
6.6
Industry
7.4
Forward
7.5
vs History
8
vs Industry
37
Median 3Y
8.3
Median 5Y
8.3
Industry
8.5
vs History
vs Industry
Median 3Y
-26.5
Median 5Y
-26.5
Industry
5.1
Forward
-76
vs History
vs Industry
Median 3Y
-20.1
Median 5Y
-20.1
Industry
4.7
Forward
-49.2
vs History
vs Industry
Median 3Y
-20.1
Median 5Y
-20.1
Industry
6.6
vs History
vs Industry
Median 3Y
-12.6
Median 5Y
-12.6
Industry
4.7
vs History
37
vs Industry
28
Median 3Y
6.2
Median 5Y
6.2
Industry
4.7

Multiples Across Competitors

DVYSR Competitors Multiples
Devyser Diagnostics AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Devyser Diagnostics AB
STO:DVYSR
2B SEK 10 -36 -44.8 -29.2
US
Abbvie Inc
NYSE:ABBV
341.5B USD 6.2 64.5 15.7 24.1
US
Amgen Inc
NASDAQ:AMGN
180.5B USD 5.8 57.7 20.2 36.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
129B USD 9.6 29.8 26.2 29
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.6B USD 12 -252.2 26.8 28.2
US
Gilead Sciences Inc
NASDAQ:GILD
105B USD 3.8 99.7 9.5 12
US
Epizyme Inc
F:EPE
94.1B EUR 1 975 -504 -548.8 -534.2
AU
CSL Ltd
ASX:CSL
142.3B AUD 6.5 36.4 22.3 27.8
US
Seagen Inc
F:SGT
39.3B EUR 19 -58.3 -62.8 -56.7
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.2B USD 15 -483 212.6 327.3
P/E Multiple
Earnings Growth
SE
D
Devyser Diagnostics AB
STO:DVYSR
Average P/E: 57.6
Negative Multiple: -36
N/A
US
Abbvie Inc
NYSE:ABBV
64.5
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.8
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -252.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.7
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -504 N/A
AU
CSL Ltd
ASX:CSL
36.4
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.3 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -483 N/A
EV/EBITDA Multiple
EBITDA Growth
SE
D
Devyser Diagnostics AB
STO:DVYSR
Average EV/EBITDA: 47.6
Negative Multiple: -44.8
N/A
US
Abbvie Inc
NYSE:ABBV
15.7
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26.2
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
39%
US
Gilead Sciences Inc
NASDAQ:GILD
9.5
10%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -548.8 N/A
AU
CSL Ltd
ASX:CSL
22.3
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -62.8 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 185.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
212.6
N/A
EV/EBIT Multiple
EBIT Growth
SE
D
Devyser Diagnostics AB
STO:DVYSR
Average EV/EBIT: 69.3
Negative Multiple: -29.2
N/A
US
Abbvie Inc
NYSE:ABBV
24.1
86%
US
Amgen Inc
NASDAQ:AMGN
36.6
95%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29
49%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
12
26%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.2 N/A
AU
CSL Ltd
ASX:CSL
27.8
59%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.7 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 173.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
327.3
N/A

See Also

Discover More
Back to Top